In the spirit of cultivating collaboration (and friendly competition), the #AskBio Enviornmental Health & Safety (EH&S) and Security team recently hosted Lab Olympics at our sites in Research Triangle Park and Philadelphia. Office- and lab-based colleagues competed in activities that combined team building with lab safety lessons. The purpose of the event is to ensure all employees understand the general lab hazards that may be present in our workplace and how to find safety equipment, review work practices, and effectively respond in emergency situations. This helps us maintain a safe environment and also helps improve performance, boost employee satisfaction, and increase the speed at which we can lead innovative science. Teams competed in more than 10 events including favorites like the rubber duck scavenger hunt with safety equipment clues, safety safari wranglers, the eyewash obstacle course, and making glove balloon animals. Winners won prizes and all participants were celebrated with a team lunch and award ceremony on the final day.
Asklepios BioPharmaceutical, Inc. (AskBio)
Biotechnology Research
Research Triangle Park, North Carolina 36,916 followers
Pioneering science to create transformative molecular medicines.
About us
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for congestive heart failure, Huntington’s disease, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, Scotland, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing. Learn more at askbio.com. Vision - Pioneering science to create transformative molecular medicines. Mission - Lead innovative science and drive clinical outcomes to transform people's lives. Values: • Be a Pioneer. We are not afraid of the impossible and to innovate to make gene therapies accessible to those in need. • Cultivate Collaboration. Strive to be the best teammate, actively listen, openly communicate, and embrace diverse points of view. • Embrace Responsibility. We are humbled by the enormity of our mission. We hold a relentless commitment to advance science and clinical outcomes for our patients, families, and caregivers. • Raise the Bar. Continuously drive improvements and efficiencies. Seek and provide constructive feedback. Have a bias for learning and action. • Act with Uncompromising Integrity. Be honest, transparent, and committed to doing what’s right in every situation. Make clear commitments and follow through.
- Website
-
http://www.askbio.com
External link for Asklepios BioPharmaceutical, Inc. (AskBio)
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Research Triangle Park, North Carolina
- Type
- Privately Held
- Founded
- 2001
- Specialties
- AAV, Adeno-Associated Virus, Gene Therapy, Rare Disease, AAV Manufacturing, Molecular Medicine, Nucleic Acid, Epigenome, and Doggybone DNA
Locations
Employees at Asklepios BioPharmaceutical, Inc. (AskBio)
-
Gustavo Pesquin
-
Doug Schantz
Senior Vice President of Clinical Operations at Asklepios BioPharmaceutical, Inc. (AskBio)
-
Kira Mourão MBCS
Principal Machine Learning Scientist at Asklepios BioPharmaceutical, Inc. - (AskBio)
-
Kara Witcoff
Patient Advocacy & External Engagement / Public Affairs / Strategic Alliances / Business Development / Global Relations
Updates
-
The #AskBio team recently left Rome, Italy and the 2024 European Society of Gene & Cell Therapy Congress, where we appreciated having the opportunity to engage in broad scientific exchange on a range of gene therapy topics, covering our pre-clinical, clinical, and manufacturing activities. We met hundreds of people who share our passion for advancing science and technology to create meaningful impacts for people living with debilitating conditions, including Parkinson's disease. A leading highlight was the oral presentation from Krystof Bankiewicz and moderated by Nathalie Cartier Lacave, which provided an update on the clinical progress and upcoming plans for AB-1005, our investigational Parkinson’s gene therapy. Big thanks to every member of our on-site team for leading our activities and to the attendees who engaged us in conversations and expressed significant interest in learning more about our current and future work. #GeneTherapy #ParkinsonsDisease #ESGCT
-
#AskBio employees are on a mission to lead innovative science. For Di Ana Zhang, a scientist with the Nanoplatform Discovery R&D team, this aligns with being a pioneer, which is one of our core values. Specifically, for Di Ana, this means not being afraid of what some may consider impossible and innovating to make gene therapies accessible to those in need. In addition, Di Ana has a strong sense of purpose knowing that her efforts and those of her colleagues may contribute to improving health and quality of life. This awareness helps inspire a commitment to excellence, driving innovation, and fostering a collaborative spirit, as each R&D achievement has the potential to make a significant difference in real lives. Interested in helping us make a difference? Visit https://lnkd.in/ejPBtp8 to explore opportunities in hashtag #GeneTherapy. Let’s make history together.
-
Two days in and two days to go at the 2024 European Society of Gene & Cell Therapy Congress. The #AskBio team is feeling energized as we meet with scientists from around the world to discuss the collective progress across the field of #GeneTherapy. We are inspired by the work happening, and are particularly proud of efforts to progress our clinical and pre-clinical pipeline and advance our manufacturing technologies. We've completed 10 of our 11 presentations and look forward to our final oral presentation on Thursday, October 24, 9:00-11:00 local time (Session 7d: CNS Gene Therapy, Auditorium PARALLEL): Clinical Progress and Plans for AB-1005 (AAV2GDNF) Gene Therapy for Parkinson's Disease. The presentation will be delivered by Krystof Bankiewicz, MD, PhD, Scientific Chair, Parkinson’s and MSA, AskBio and co-chaired by Nathalie Cartier Lacave, MD, Senior Vice President, Sector Lead, Neurobiology, AskBio. Visit us at booth D19 to learn more about all we are doing. #Leadership #ESGCT2024 Danielle Green, Meg Heim, Krishen Somers, Roger Hajjar, Scott Hammond, Amber Van Laar, Madhuvanthi Vijayan Ph.D., Krystof Bankiewicz, Marco Zahn, Kathleen Boerner, Emma Smith, PhD, Micol Alberti, Rachael Di Santo; Graham W., Enejda Subashi, Sandro Alves, Nathalie Cartier Lacave, Ralph Herbst, Christian Blaszkewicz, Eva-Maria Wicklein, Kristian Johnson, Karen Bulaklak, Ph.D., Juan Enrique Ortiz, M.D. BCMAS
-
We're excited to be in Rome, Italy, from October 22 to 25, for this year's European Society of Gene & Cell Therapy Congress. The #AskBio team will deliver 11 presentations, including two orals, as well as meet with physicians and others to discuss the exciting progress taking place in our clinical and pre-clinical pipeline and advancements in our manufacturing technologies. Visit us at booth D19. #Leadership #GeneTherapy #ESGCT2024 Kristian Johnson; Madhuvanthi Vijayan Ph.D.; Danielle Green; Graham W.; Scott Hammond; Karen Bulaklak, Ph.D.; Juan Enrique Ortiz, M.D. BCMAS; Rachael Di Santo; @Eva-Maria Wicklein
-
We are thrilled to be in Rome, Italy, next week to deliver 11 presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting. The two oral and nine poster presentations highlight exciting progress in the #AskBio clinical and pre-clinical pipeline and advancements in our manufacturing technologies. Alongside recent clinical program milestones, the presentations demonstrate our commitment to advancing our end-to-end capabilities and our goal of delivering breakthrough therapies. For Medical Media – Read our press release here: https://lnkd.in/esFnVFcs #GeneTherapy #ESGCT2024
-
Today is World Mental Health Day, a day aimed at raising awareness about the importance of mental health and well-being in our lives, both professionally and personally. This year's theme is focused on prioritizing mental health in the workplace. The #AskBio employee assistance program and our flexible paid time off benefits help provide our employees with resources and tools to support their well-being. In addition to our more formal support, we encourage colleagues to form employee resource groups (ERGs), which add to our vibrant workplace culture by sponsoring events, providing information/education, and engaging in important conversations. On this important day, we’re proud to announce that we’re expanding our ERG network with our newest group, Minds of All Kinds. Co-founded by James Aykit and Amanda Carson. This ERG's mission is to empower those with neurodivergent, intellectual, and mental health differences by providing a safe space for learning, feedback, coaching, and education. Minds of All Kinds was created based on feedback from and the success of our Disability Pride event in July. We believe that when we can provide an inclusive environment for employees to reach their fullest potential, we are best suited to lead innovative science and drive clinical outcomes, which may transform people's lives. #MentalHealthMatters #WellbeingAtWork #WorldMentalHealthDay #Leadership #GeneTherapy
-
More than 50 #AskBio employees in the US and Europe recently participated in the Path to A Cure: Mission MSA Virtual Walk to support patients and families affected by multiple system atrophy (MSA). Our collective participation helped spread awareness to better understand and support people battling this complex disease. Patients are our North Star, and their resilience continues to be an inspiration for our mission of leading innovative science and driving clinical outcomes that may transform people's lives. Thanks to Mission MSA for providing us with this opportunity to come together as a team, across locations and time zones, and play a small role in helping them carry out their important work. #MissionMSA #PathToACure5K #RareDisease #WorldMSADay #GeneTherapy Alan Walsh ACA; Albana Alili Dalipi; Anand Thaker; Candace Summerford, Ph.D.; Cara Davis; Christopher Allen; Danielle Green; Deb Cole, CCDM; Ellen Kelly; Emily Slocum; Farah CHALI; Heather Caro, MBA BSN; Jane Williamson; Jason Krentz; Jen Barger Fleming, PhD DABT; Jenny Siferd, SPHR; Kara Witcoff; Mary Shaffer; Melissa Murrell; Minnal Gupta; Philip McNamara; Rosheen Caw; Susan Kratky; Tracy Dowling; Victor Stukat Gren; Kavonne Brooks; Gustavo Pesquin
-
The #AskBio team earlier this week wrapped up five days in Philadelphia, PA, at this year's International Congress of Parkinson's Disease and Movement Disorders. Thank you to the hundreds of attendees who visited our booth, attended our presentations, and took time to discuss with us the many exciting gene therapy developments that are unfolding at AskBio and across the Parkinson's disease landscape. A leading highlight was the presentation of our 36-month Phase 1b Parkinson’s investigational clinical trial data, which demonstrate encouraging current clinical stability of AB-1005 at 3 years. We look forward to continued follow up, which will help assess even longer term durability. We were also excited to present the design of our currently recruiting Phase 2 REGENERATE-PD trial. Fielding dozens of questions at our booth, we were energized by the significant interest in learning more about gene therapy. To learn more about these clinical trials, please visit clinicaltrials.gov (NCT 04167540 and NCT 06285643). We are excited about the potential of our advancing investigational gene therapy therapeutic options and by the meaningful impact our innovations could one day have for PD patients. Thanks to all the members of the AskBio team for their hard work over a busy and important few days. #Leadership #GeneTherapy #ParkinsonsDisease Adrian Kells, Akash P., Amber Van Laar, Chantal Letourneau, Christian Urrea, MD, Ellie (Yiqun) Hu), Juan Enrique Ortiz, M.D. BCMAS, Nisha Chhabria MD, FAAN, Steven Elmes, Waldy San Sebastian
-
We're excited to welcome Cristobal Passalacqua, MD who recently joined the #AskBio Global Clinical Development team as Vice President of Neuromuscular Clinical Development. Chris will be responsible for developing limb-girdle muscular dystrophy (LGMD) and Pompe studies as we work to advance these programs in the clinic. He describes himself as an optimist who believes there is always a solution or at least a positive way to deal with a situation. This mantra has supported Chris throughout his career in clinical development, where every day there are new challenges that may seem “too big” or “too complicated” to solve. #Leadership #GeneTherapy